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most patients but less than 5% of patients achieve a molecular
remission. Therefore, combination regimens consisting of alloge-
neic HSCT and imatinib have been proposed. We used murine
models of allogeneic HSCT to investigate the effects of imatinib
administration in the peri-transplant period. We used an MHC-
matched allogeneic HSCT model (B10.BR 3 CBA) and a con-
genic syngeneic HSCT model (Ly5.1 3 B6). All mice received
lethal doses of radiation followed by injection of 5  106 T-cell
depleted bone marrow cells. Imatinib was administered via intra-
peritoneal injection twice daily from day 1 to day 8 of transplant
at a dose of 45 mg/kg/dose. In the congenic model, all imatinib-
treated mice died by day 8 whereas control mice had 100% survival
(combined data of 2 transplants; n16; p
0.0001). Similarly, the
imatinib-treated mice in the allogeneic HSCT model had inferior
survival compared to controls (p0.0001). We analyzed imatinib-
treated allogeneic HSCT recipients on day 14 and found that
thymocyte counts were signiﬁcantly reduced in the imatinib
treated group (0.96  106) compared to controls (8.2  106)
(p
0.00002). The numbers of CD4, CD8 and double positive
thymocytes were also signiﬁcantly reduced. Total splenocyte
counts were diminished in the imatinib-treated group as well, but
the difference was not signiﬁcant (29.8  106 vs. 37.3  106). The
numbers of splenic CD3 T cells, B220 B cells and NK1.1 NK
cells were signiﬁcantly reduced in the imatinib-treated allogeneic
HSCT recipients. We found no differences in the total number of
bone marrow cells or CFU-GM or BFU-E colonies in imatinib-
treated mice versus controls. We performed weekly complete
blood counts and noted signiﬁcant decreases in the hemoglobin
concentration (day 7 and 14), platelets (day 7) and lympho-
cytes (day 21). In conclusion, peri-transplant administration of
imatinib to recipients of a syngeneic or allogeneic T-cell depleted
HSCT results in signiﬁcant mortality, which is associated with
profound defects in T-, B- and NK-lymphopoiesis, as well as
moderate decreases in erythrocyte and platelet recovery.
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CD4V11 T CELLS EXHIBIT LIMITED TCR- REPERTOIRE DIVER-
SITY IN THE miHA-MATCHED C57BL/6 3 BALB.B MODEL OF GRAFT-
VERSUS-HOST DISEASE
DiRienzo, C.G.; Friedman, T.; Korngold, R. Thomas Jefferson Univer-
sity Kimmel Cancer Center, Philadelphia, PA.
Spectratype analysis of the TCR V chain is a useful tool for
examining the T cell repertoire of clonally expanded populations of
T cells responding to minor histocompatibility antigens (miHAs)
during graft-versus-host disease (GVHD). The nature of miHAs in
the CD4-mediated, H2b-matched C57BL/6 3 BALB.B model
remains elusive, but previous spectratype analysis demonstrated a
vital role for CD4V11 T cells in mediating GVHD. Transfer
of C57BL/6 CD4V11T cells, along with T cell-depleted bone
marrow, caused lethal GVHD in BALB.B mice. The TCR V
chain alone does not determine the speciﬁcity of peptide-MHC
recognition. The speciﬁcity of peptide-MHC recognition is mainly
determined by the CDR1 and CDR3 loops of both the TCR- and
- chains. Evidence from crystallographic studies, TCR- trans-
genic mice, and tumor-reactive T cells from humans showed that
a single TCR- chain could pair with multiple TCR- chains and
still maintain peptide speciﬁcity. These studies suggest that the
TCR- chain may have a predominant role in antigen recognition.
Analysis of the TCR- chain has not been previously examined
using the well-characterized system of spectratype analysis. Upon
transplant of unfractionated C57BL/6 CD4 T cells into lethally
irradiated BALB.B recipients, analysis of the TCR- repertoire
within the BALB.B-reactive CD4V11 C57BL/6 T cell popu-
lation was performed on day 10. Our data show that there is limited
V diversity in the CD4V11 response to BALB.B miHAs. The
limited TCR diversity seen with both the V and V chains
suggests that C57BL/6 CD4 T cells recognize a limited number
of antigenic peptides in this model.
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PURE RED CELL APLASIA (PRCA) FOLLOWING ABO-INCOMPATIBLE
ALLOGENEIC BONE MARROW TRANSPLANTATION
Sethi, S.1,2; Hamadani, M.H.1; Kamble, R.1,2; Kharfan-Dabaja, M.1,2;
Ozer, H.1,2; Selby, G.S.1,2 1. Department of Internal Medicine, Okla-
homa University Health Sciences Center, Oklahoma City, OK; 2. Section
of Hematology and Oncology and Bone Marrow Transplantation, Okla-
homa University Health Sciences Center, Oklahoma City, OK.
Background: Pure red cell aplasia (PRCA) following ABO in-
compatible allogenic BMT has been reported. The treatment of
PRCA varies widely with no clear consensus amongst transplant
institutions. Method: 3 patients were found to have PRCA. Ret-
rospective analysis of patients and treatment characteristics of these
forms the basis of this report. In addition, we provide systemic
review of the treatment of PRCA following allogeneic transplant
from the published literature. Results: All 3-patients had acute
myelogenous leukemia and received graft from ABO incompatible
donor. The median age was 49 years (range  39–62). Condition-
ing and GVHD prophylaxis included, CY/TBI 2, BU/CY1,
Cyclosporine  Methotrexate  3. Median time to PRCA from
the date of transplant was 30 weeks (range 13–32). Two patients
received treatment with prednisone at 1 mg/kg; one patient was
treated with Erythropoietin alone. Median time to respond and
transfusion independence in steroid treated patients was 15 days
(data not available for patient treated with Erythropoietin). Total
of 39 published reports describe 60 patients with PRCA following
ABO mismatch allogeneic transplant. The successful treatment of
PRCA varies widely and include, no treatment (spontaneous res-
olution)  15, Cyclosporine discontinuation 4, tapering of cy-
closporine and onset of GVHD  2, reinstitution of cyclospor-
ine  1, Erythropoietin alone  7, Steroids alone  4, Steroids 
Erythropoietin  1, Plasmapheresis  10, Immuno-adsorption
aphaeresis  4, Antilymphocyte globulin  2, Antithymocyte
globulin 2, Rituximab 2, Donor leukocyte infusion (DLI) 2.
Treatment details were not available in 4 reports. The median time
to response (transfusion independence) is available in 19/60 pa-
tients. Median time to response was higher in patients with DLI
and immunotherapy (observation/erythropoietin/steroids/CSA ta-
pering 56 days, ATG/ALG/Rituximab/DLI 69).Conclusion:
Initial management with observation, cyclosporine tapering, eryth-
ropoietin with or without steroids results in resolution of PRCA in
over 50% patients. Refractory patients should be treated with
plasmapheresis, immuno-adsorption aphaeresis, immunotherapy
(ATG, ALG, Rituximab, DLI) in that order.
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PROGNOSTIC FACTORS FOR ALLOGENEIC STEM CELL TRANSPLANTA-
TION (ASCT) FOR UNTREATED FIRST RELAPSE OF ACUTE MYELOID
LEUKEMIA (AML)/MYELODYSPLASTIC SYNDROME (MDS)
Alamo, J.G.; Shahjahan, M.; Wong, R.S.; de Lima, M.; Khouri, I.;
Gajewski, J.; Couriel, D.; Andersson, B.S.; Anderlini, P.; Champlin, R.;
Giralt, S. University of Texas M.D. Anderson Cancer Center, Houston,
TX.
Introduction: The treatment of patients relapsing after primary
therapy for Acute Myeloid Leukemia or High Risk Myelodysplas-
tic Syndromes is controversial. Although many centers recommend
proceeding to allografting if a donor is available without re-induc-
tion therapy, the data on which this recommendation is based is
limited, because of small numbers and patient heterogeneity.
Methods: To determine potential clinical factors that could allow
physicians to decide which patients with ﬁrst relapse AML/MDS
could beneﬁt or not from re-induction therapy we performed a
retrospective analysis of 81 patients (39 males; 42 females) who
received ASCT for untreated AML after First Relapse (n60),
MDS (n13) and MDS/AML (n8) between 01/1989 and 02/
2003 at M.D. Anderson Cancer Center. Results: Median age was
39 years (range 17–68). The median time interval from diagnosis
to transplant was 0.7 years (range 0.22–4.23). 73 patients received
transplant from related donors (63 siblings, 5 children, 5 parents)
and 8 from matched unrelated donors. Preparative regimens in-
cluded TBI based (n20), FM	 ATG (n10), FB	 ATG, Bu/Cy
(n11), Bu/Cy/TT (n18), BuCyDAC (n2), others (n8).
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